Product Overview:
Ibrutinib, marketed under the brand name Imbruvica, is a small molecule pharmaceutical agent acting as an inhibitor of B-cell proliferation and survival. It achieves this by irreversibly binding to Bruton's tyrosine kinase (BTK), a protein crucial in B-cell signaling. By blocking BTK, Ibrutinib disrupts the B-cell receptor pathway, a pathway that is frequently abnormally active in B-cell malignancies. Consequently, Ibrutinib is employed in the treatment of various cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia. Ibrutinib also exhibits binding affinity to C-terminal Src Kinases. These serve as off-target receptors for this BTK inhibitor. The binding of Ibrutinib to these receptors prevents the kinase from promoting cellular differentiation and growth. This interaction can precipitate a range of adverse effects, such as left atrial enlargement and atrial fibrillation, during the treatment of Chronic Lymphocytic Leukemia.
Imbruvica Dosage Guidelines:
The recommended initial dosage of Imbruvica varies based on the specific condition being treated. Examples of common dosages include:
- Mantle cell lymphoma: 560mg once daily
- Marginal zone lymphoma: 560mg once daily
- Waldenstrom's macroglobulinemia: 420mg once daily
- Chronic lymphocytic leukemia (CLL): 420mg once daily
- Small lymphocytic lymphoma: 420mg once daily
- Chronic graft-versus-host disease: 420mg once daily.
Dosage adjustments may be necessary in cases of toxicity. Typically, Imbruvica administration continues until disease progression, unacceptable toxicity, or, in the instance of graft versus host disease, the recurrence of an underlying malignancy.
Mechanism of Action: Understanding Imbruvica
Ibrutinib is a targeted therapy that functions by inhibiting the enzyme Bruton tyrosine kinase (BTK). This enzyme is a critical component of a vital signaling pathway in specific cancers, particularly B-cell leukemias and lymphomas.
By obstructing this pathway, Imbruvica induces the death of cancerous cells. Imbruvica finds utility in the treatment of:
- Mantle cell lymphoma
- Marginal zone lymphoma
- Waldenstrom's macroglobulinemia
- Chronic lymphocytic leukemia
- Small lymphocytic lymphoma.
Furthermore, Imbruvica may be prescribed for the management of chronic graft-versus-host disease.
Why Choose Extract Makers?
We have over 8 years of expertise as a leading supplier and researcher of pharmaceutical raw materials, plant extracts, and health care ingredients. Our collaborations extend globally, encompassing customers in China, the USA, Europe, the Middle East, Southeast Asia, and various other regions.
Health, Youth, Passion, and Service define our core values.
We offer a broader selection of high-quality steroids. If you have any inquiries, please contact us via email at:
Email: [email protected]
